中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.017 seconds)

    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
    3.
    发明申请
    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 审中-公开
    白细胞介素-17F抗体和其他IL-17F信号拮抗剂及其用途

    公开(公告)号：WO2006088833A3

    公开(公告)日：2006-11-23

    申请号：PCT/US2006005111

    申请日：2006-02-14

    Applicant: WYETH CORP ,  CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

    Inventor： CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

    IPC: C07K16/24 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61P29/00 ,  A61P37/00 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/113 ,  G01N33/68

    CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

    Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

    Abstract translation: 本发明提供了与IL-17F信号传导途径相关的分离和纯化的多核苷酸和多肽。 本发明还提供针对IL-17F同二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异二聚体）的方法。 本发明还涉及用于诊断，预测，监测IL-17F信号传导即IL-17F相关病症（包括但不限于炎症）的进展和治疗和/或预防与IL-17F信号传导相关的病症的新方法 （例如，关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，变态反应），移植排斥（包括实体器官移植排斥 ）和炎性肠病或病症（IBD，例如溃疡性结肠炎，克罗恩氏病）。 本发明还涉及新的治疗剂和治疗靶，以及筛选和评估测试化合物用于干预（治疗）和预防与IL-17F信号传导相关的病症的方法。

    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES
    5.
    发明申请
    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES 审中-公开
    蛋白激酶C ZETA作为ARTHRITIS和其他炎症疾病的药物目标

    公开(公告)号：WO2004104217A3

    公开(公告)日：2005-11-24

    申请号：PCT/US2004014759

    申请日：2004-05-10

    Applicant: WYETH CORP ,  LAVALLIE EDWARD R ,  COLLINS-RACIE LISA A ,  ARAI MAYA

    Inventor： LAVALLIE EDWARD R ,  COLLINS-RACIE LISA A ,  ARAI MAYA

    IPC: A61K31/00 ,  A61K31/415 ,  A61K31/7105 ,  A61K38/00 ,  C12N15/11 ,  C12Q1/00 ,  C12Q1/48 ,  C12Q1/68 ,  G01N33/564 ,  G01N33/68

    CPC classification number: G01N33/564 ,  G01N33/6872 ,  G01N2333/91215 ,  G01N2500/00 ,  G01N2800/102

    Abstract: The present invention is based on the discovery that zetaPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased zetaPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of zetaPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.

    Abstract translation: 本发明基于与正常个体相比，关节炎患者组织中zetaPKC表达增加的发现。 因此，本发明提供了基于关节炎组织中增加的zetaPKC基因表达来诊断，预测和监测患者关节炎过程的方法。 本发明还提供抑制zetaPKC表达用作治疗关节炎的药物的化合物，包括但不限于抑制性多核苷酸和多肽，小分子和肽抑制剂。 此外，本发明提供了药物制剂和用于此类治疗方法的给药途径，以及评估其疗效的方法。

    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES
    6.
    发明申请
    PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES 审中-公开
    蛋白激酶C ZETA作为ARTHRITIS和其他炎症疾病的药物目标

    公开(公告)号：WO2004104217A2

    公开(公告)日：2004-12-02

    申请号：PCT/US2004/014759

    申请日：2004-05-10

    Applicant: WYETH ,  LAVALLIE, Edward, R. ,  COLLINS-RACIE, Lisa, A. ,  ARAI, Maya

    Inventor： LAVALLIE, Edward, R. ,  COLLINS-RACIE, Lisa, A. ,  ARAI, Maya

    IPC: C12Q1/00

    CPC classification number: G01N33/564 ,  G01N33/6872 ,  G01N2333/91215 ,  G01N2500/00 ,  G01N2800/102

    Abstract: The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.

    Abstract translation: 本发明基于与正常个体相比，关节炎患者组织中zetaPKC表达增加的发现。 因此，本发明提供了基于关节炎组织中增加的zetaPKC基因表达来诊断，预测和监测患者关节炎过程的方法。 本发明还提供抑制zetaPKC表达用作治疗关节炎的药物的化合物，包括但不限于抑制性多核苷酸和多肽，小分子和肽抑制剂。 此外，本发明提供了药物制剂和用于此类治疗方法的给药途径，以及评估其疗效的方法。

    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
    7.
    发明申请
    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 审中-公开
    白细胞介素-17F抗体及其他IL-17F信号拮抗剂及其用途

    公开(公告)号：WO2006088833A2

    公开(公告)日：2006-08-24

    申请号：PCT/US2006/005111

    申请日：2006-02-14

    Applicant: WYETH ,  CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

    Inventor： CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

    IPC: C07K16/24 ,  C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/11 ,  G01N33/68 ,  A61K39/39 ,  A61K39/395 ,  A61P37/00 ,  A61P29/00 ,  A61K38/20

    CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

    Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

    Abstract translation: 本发明提供与IL-17F信号通路相关的分离和纯化的多核苷酸和多肽。 本发明还提供了对IL-17F同源二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异源二聚体）的方法。 本发明还涉及用于诊断，预后，监测与IL-17F信号传导相关的疾病的进展和/或预防的新方法，即IL-17F相关疾病，包括但不限于炎性 诸如自身免疫性疾病（例如关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，过敏），移植排斥（包括实体器官移植排斥 ）和炎症性肠病或疾病（IBD，例如溃疡性结肠炎，克罗恩病）。 本发明还涉及新的治疗和治疗靶标，以及筛选和评估用于干预（治疗）的试验化合物和预防与IL-17F信号传导相关的紊乱的方法。

Patent Agency Ranking